Alto Neuroscience Q1 net loss $13.4M; cash $205.9M; pipeline on track for multiple readouts

Alto Neuroscience, Inc.

2024-Q1 EPS reported -$0.76

Net loss $13.4M vs $7.3M YoY; R&D expenses $10.0M, G&A $4.4M, both up on clinical study costs and public company expenses.
Cash and equivalents $205.9M as of March 31, 2024; expects to fund operations into 2027.
Initiated Phase 2 study of ALTO-203 in MDD with anhedonia; reported positive Phase 1 data for transdermal ALTO-101 with improved tolerability.
Phase 2b studies of ALTO-100 and ALTO-300 in MDD enrolling; topline data for ALTO-100 expected 2H 2024, ALTO-300 1H 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Alto Neuroscience, Inc. reported financial results for the first quarter ended March 31, 2024.

Period: the first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

Alto Neuroscience, Inc. (the "Company") reported financial results for the fiscal quarter ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Alto Neuroscience, Inc. filing history →

Source: SEC EDGAR

accession 0001999480-24-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.